The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is above average at 30.11x. The 36-month beta value for AZN is also noteworthy at 0.43. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for AZN is 3.10B, and at present, short sellers hold a 0.34% of that float. The average trading volume of AZN on April 14, 2025 was 6.17M shares.
AZN) stock’s latest price update
Astrazeneca plc ADR (NASDAQ: AZN)’s stock price has plunge by 2.35relation to previous closing price of 66.29. Nevertheless, the company has seen a 3.13% surge in its stock price over the last five trading sessions. zacks.com reported 2025-04-14 that AbbVie’s, Rinvoq and AstraZeneca’s and Novartis are included in this Analyst Blog.
AZN’s Market Performance
AZN’s stock has risen by 3.13% in the past week, with a monthly drop of -12.56% and a quarterly rise of 3.23%. The volatility ratio for the week is 5.30% while the volatility levels for the last 30 days are 2.60% for Astrazeneca plc ADR The simple moving average for the last 20 days is -5.00% for AZN stock, with a simple moving average of -8.47% for the last 200 days.
AZN Trading at -7.53% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.61% of loss for the given period.
Volatility was left at 2.60%, however, over the last 30 days, the volatility rate increased by 5.30%, as shares sank -11.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.72% lower at present.
During the last 5 trading sessions, AZN rose by +3.56%, which changed the moving average for the period of 200-days by -13.85% in comparison to the 20-day moving average, which settled at $71.44. In addition, Astrazeneca plc ADR saw 3.56% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.81 for the gross margin
The net margin for Astrazeneca plc ADR stands at 0.13. The total capital return value is set at 0.13. Equity return is now at value 17.60, with 6.86 for asset returns.
Based on Astrazeneca plc ADR (AZN), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is 5.74.
Currently, EBITDA for the company is 17.12 billion with net debt to EBITDA at 1.43. When we switch over and look at the enterprise to sales, we see a ratio of 4.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
In summary, Astrazeneca plc ADR (AZN) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
